NIH Launches Large Randomized Trial to Determine Utility of PGx-based Warfarin Dosing
February 18, 2009
NIH Launches Large Randomized Trial to Determine Utility of PGx-based Warfarin Dosing
NHLBI plans to launch next month the prospectively designed, randomized-controlled study, called Clarification of Optimal Anticoagulation through Genetics trial, which will follow 1,200 patients to see if PGx-guided dosing is clinically useful.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genetics Improves Some Warfarin Dosing; Clinical Trials Next
February 19, 2009 / GenomeWeb Daily News - FDA Updates Warfarin Labeling with PGx-Guided Dosing Ranges
February 3, 2010 / Pharmacogenomics Reporter - US Gov't Stimulus Package Could Be 'Boon' for Bioinformatics, NIH Officials Say
April 10, 2009 / BioInform - NIH Posts Call for $200M in Stimulus Grants
March 5, 2009 / GenomeWeb Daily News - Snippets
March 4, 2009 / Pharmacogenomics Reporter